JP2015531747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531747A5 JP2015531747A5 JP2015517810A JP2015517810A JP2015531747A5 JP 2015531747 A5 JP2015531747 A5 JP 2015531747A5 JP 2015517810 A JP2015517810 A JP 2015517810A JP 2015517810 A JP2015517810 A JP 2015517810A JP 2015531747 A5 JP2015531747 A5 JP 2015531747A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- alkyl
- therapeutic agent
- optionally substituted
- thieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atoms Chemical group C* 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cells Anatomy 0.000 claims 5
- 230000003211 malignant Effects 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- -1 diazepine compound Chemical class 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000004683 dihydrates Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 206010062113 Splenic marginal zone lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 101710017890 large T Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Claims (6)
- 式1:
- B細胞悪性癌がびまん性大細胞型B細胞リンパ腫である、請求項1に記載の治療剤。
- B細胞悪性癌が脾臓周辺帯リンパ腫である、請求項1に記載の治療剤。
- T細胞悪性癌が未分化大T細胞リンパ腫である、請求項1に記載の治療剤。
- 式1により表されるチエノトリアゾロジアゼピン化合物が、独立して、(i)(S)−2−[4−(4−クロロフェニル)−2,3,9−トリメチル−6H−チエノ[3,2−f][1,2,4]トリアゾロ−[4,3−a][1,4]ジアゼピン−6−イル]−N−(4−ヒドロキシフェニル)アセトアミドまたはその二水和物、(ii)メチル(S)−{4−(3’−シアノビフェニル−4−イル)−2,3,9−トリメチル−6H−チエノ[3,2−f][1,2,4]トリアゾロ[4,3−a][1,4]ジアゼピン−6−イル}アセタート、(iii)メチル(S)−{2,3,9−トリメチル−4−(4−フェニルアミノフェニル)−6H−チエノ[3,2−f][1,2,4]トリアゾロ[4,3−a][1,4]ジアゼピン−6−イル}アセタート、および(iv)メチル(S)−{2,3,9−トリメチル−4−[4−(3−フェニルプロピオニルアミノ)フェニル]−6H−チエノ[3,2−f−][1,2,4]トリアゾロ[4,3−a][1,4]ジアゼピン−6−イル}アセタートから選択される、請求項1から4のいずれか1項に記載の治療剤。
- 有効成分が(S)−2−[4−(4−クロロフェニル)−2,3,9−トリメチル−6H−チエノ[3,2−f][1,2,4]トリアゾロ−[4,3−a][1,4]ジアゼピン−6−イル]−N−(4−ヒドロキシフェニル)アセトアミドまたはその二水和物である、請求項1から4のいずれか1項に記載の治療剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663885P | 2012-06-25 | 2012-06-25 | |
US61/663,885 | 2012-06-25 | ||
US201261670918P | 2012-07-12 | 2012-07-12 | |
US61/670,918 | 2012-07-12 | ||
PCT/EP2013/063313 WO2014001356A1 (en) | 2012-06-25 | 2013-06-25 | Method of treating lymphoma using thienotriazolodiazepine compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015531747A JP2015531747A (ja) | 2015-11-05 |
JP2015531747A5 true JP2015531747A5 (ja) | 2016-07-28 |
JP6265979B2 JP6265979B2 (ja) | 2018-01-24 |
Family
ID=48672651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015517810A Expired - Fee Related JP6265979B2 (ja) | 2012-06-25 | 2013-06-25 | チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140018353A1 (ja) |
EP (1) | EP2863923B1 (ja) |
JP (1) | JP6265979B2 (ja) |
KR (1) | KR20150045423A (ja) |
CN (1) | CN105050605A (ja) |
AU (1) | AU2013283378B2 (ja) |
BR (1) | BR112014032105A2 (ja) |
CA (1) | CA2877434A1 (ja) |
IN (1) | IN2014DN11269A (ja) |
MX (1) | MX2014015986A (ja) |
RU (1) | RU2659171C2 (ja) |
WO (1) | WO2014001356A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2666530C2 (ru) | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
WO2014143768A1 (en) | 2013-03-15 | 2014-09-18 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
EP3027194A1 (en) * | 2013-08-01 | 2016-06-08 | Oncoethix GmbH | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
US20160158246A1 (en) * | 2013-08-06 | 2016-06-09 | Oncoethix Gmbh | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9757385B2 (en) | 2013-11-27 | 2017-09-12 | Merck Sharp & Dohme Corp. | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
BR112016024626B1 (pt) | 2014-04-23 | 2023-03-21 | Incyte Holdings Corporation | Compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7 (6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet |
AU2015252844A1 (en) | 2014-05-02 | 2016-11-03 | Kay NOEL | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
KR20170002550A (ko) * | 2014-05-02 | 2017-01-06 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 사용한 내성 비호지킨 림프종, 수아세포종, 및/또는 alk+ 비소세포 폐암의 치료 방법 |
JP2017519727A (ja) | 2014-05-08 | 2017-07-20 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 |
EP3154549A1 (en) | 2014-06-13 | 2017-04-19 | Oncoethix GmbH | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
WO2016026912A1 (en) * | 2014-08-19 | 2016-02-25 | Oncoethix Gmbh | Methods of treating lymphoma using thienotriazolodiazepine compounds |
EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
KR101675984B1 (ko) * | 2015-02-23 | 2016-11-14 | 한양대학교 에리카산학협력단 | 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물 |
WO2016149668A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
PE20190623A1 (es) | 2016-06-20 | 2019-04-26 | Incyte Corp | Formas solidas cristalinas de un inhibidor de bet |
JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
CN108070562A (zh) * | 2018-02-03 | 2018-05-25 | 金华市中心医院 | 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法 |
AU2019251223A1 (en) | 2018-04-13 | 2020-11-26 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006802A1 (en) | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
DE69717160T2 (de) * | 1996-09-13 | 2003-05-08 | Mitsubishi Pharma Corp | Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen |
KR101600634B1 (ko) * | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
SI2902030T1 (sl) * | 2010-05-14 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Tienotriazolodiazepinske spojine za zdravljenje neoplazije |
JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
WO2013033420A1 (en) * | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
-
2013
- 2013-06-25 IN IN11269DEN2014 patent/IN2014DN11269A/en unknown
- 2013-06-25 MX MX2014015986A patent/MX2014015986A/es unknown
- 2013-06-25 JP JP2015517810A patent/JP6265979B2/ja not_active Expired - Fee Related
- 2013-06-25 RU RU2015101106A patent/RU2659171C2/ru not_active IP Right Cessation
- 2013-06-25 CN CN201380045846.0A patent/CN105050605A/zh active Pending
- 2013-06-25 US US13/926,029 patent/US20140018353A1/en not_active Abandoned
- 2013-06-25 WO PCT/EP2013/063313 patent/WO2014001356A1/en active Application Filing
- 2013-06-25 KR KR20157000782A patent/KR20150045423A/ko active Search and Examination
- 2013-06-25 EP EP13730912.6A patent/EP2863923B1/en not_active Not-in-force
- 2013-06-25 BR BR112014032105A patent/BR112014032105A2/pt not_active Application Discontinuation
- 2013-06-25 CA CA2877434A patent/CA2877434A1/en not_active Abandoned
- 2013-06-25 AU AU2013283378A patent/AU2013283378B2/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015531747A5 (ja) | ||
RU2015101106A (ru) | Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения | |
JP2016529246A5 (ja) | ||
RU2012125971A (ru) | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных | |
RU2013104520A (ru) | Пирролопиримидиновые соединения и их применения | |
JP2016523270A5 (ja) | ||
JP2020517616A5 (ja) | ||
JP2017511357A5 (ja) | ||
HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
JP2016501185A5 (ja) | ||
JP2010523670A5 (ja) | ||
JP2008535902A5 (ja) | ||
JP2016525563A5 (ja) | ||
JP2015535277A5 (ja) | ||
RU2015133528A (ru) | Замещенные полициклические пиразольные ингибиторы киназной активности и их применение | |
JP2017517579A5 (ja) | ||
EA201401063A1 (ru) | Алкил 2-{[(2r,3s,5r)-5-(4-амино-2-оксо-2h-пиримидин-1-ил)-3-гидрокситетрагидрофуран-2-илметокси]феноксифосфориламино}пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения | |
RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
JP2017517538A5 (ja) | ||
RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
JP2013502441A5 (ja) | ||
JP2012512863A5 (ja) | ||
JP2021501208A5 (ja) | ||
JP2015502371A5 (ja) |